Ideaya and Servier Announce Data From Three Uveal Melanoma Trials
The companies announced data from three clinical trials at ESMO 2026 on darovasertib for uveal melanoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
IDEAYA Biosciences and Servier report data from three ESMO 2026 clinical trials
The companies say the data support the potential of darovasertib as a therapy for uveal melanoma. The alert provides no trial results or further details.